Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 1Phase 2 1

Status

Completed 3Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 2

Study Type

Interventional 6

Sponsor

Cancer Type

CNS 6Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 209Lung Neoplasms 80Breast Neoplasms 68Triple Negative Breast Neoplasms 67Ovarian Neoplasms 57Squamous Cell Carcinoma of Head and Neck 50Small Cell Lung Carcinoma 44Fallopian Tube Neoplasms 38Endometrial Neoplasms 33Neoplasms 30Parkinson Disease 4, Autosomal Dominant Lewy Body 28Neoplasm Metastasis 28Head and Neck Neoplasms 24Prostatic Neoplasms 20Carcinoma 18Esophageal Neoplasms 17Urinary Bladder Neoplasms 16Colorectal Neoplasms 16Uterine Cervical Neoplasms 15Oropharyngeal Neoplasms 14Carcinoma, Transitional Cell 14Carcinoma, Squamous Cell 14Esophageal Squamous Cell Carcinoma 13Brain Neoplasms 12Stomach Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Mouth Neoplasms 9Laryngeal Neoplasms 9Carcinoma, Ovarian Epithelial 9

Interventions

Temozolomide 99Radiotherapy 51Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 20Lomustine 16Nivolumab 14Surgical Procedures, Operative 11Cyclophosphamide 8Biopsy 8atezolizumab 7abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6olaparib 5Metformin 5Diet, Ketogenic 5Dianhydrogalactitol 5Aminolevulinic Acid 5regorafenib 4poly ICLC 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4Etoposide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Glioblastoma × Carboplatin × 1 year × Clear all
NCT05902169 2026-04-24

SONOBIRD

CarThera

Phase 3 Recruiting
560 enrolled
CNS

Glioblastoma

NCT04528680 2026-04-13

SC9/ABX

Northwestern University

Phase 1/2 Active not recruiting
57 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04417088 2026-03-20

Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy

InSightec

Phase 1/2 Completed
28 enrolled
CNS

Glioblastoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT04440358 2026-01-20

Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM

InSightec

Phase 1/2 Completed
13 enrolled
CNS

Glioblastoma

NCT04740190 2025-06-11

TAC-GReD

The University of Hong Kong

Phase 2 Completed
33 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡